|
|
Interim Report |
|
|
SciBase receives first commercial order in the US from private clinic in New York |
|
|
SciBase receives order of up to 1 million SEK within a new customer segment in Italy |
|
|
SciBase letter from the CEO number 4: Updated strategy and securing our long-term capital needs |
|
|
NOTICE TO ATTEND EXTRAORDINARY GENERAL MEETING IN SCIBASE HOLDING AB (PUBL) |
|
|
SciBase Holding AB (publ) proposes a preferential rights issue of SEK 85 million, secured to SEK 75 million |
|
|
The following people have been appointed as members of SciBase Holding's election committee for the Annual General Meeting in 2018: |
|
|
Nevisense presented as one of the top ten most important news stories within skin cancer for dermatologists at US congress |
|
|
SciBase unveils growth strategy including plans for US launch of Nevisense |
|
|
SciBase presents the next generation Nevisense and a new type of electrode for the evaluation of New Applications |
